The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In mid-June, several biotech and navigation firms restructured their debt through convertible note offerings. Adaptive Biotechnologies upsized its offering to $300 million to repay an OrbiMed purchase agreement and repurchase common stock, while NextNav announced the redemption of its 2028 senior secured notes. Additionally, NeoGenomics priced a $275 million offering of convertible senior notes as part of this broader financial trend.